Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipoxen reports positive results from Phase I EPO trial
This large Phase I trial was a randomized, double-blind, placebo-controlled single dose study and comprised 64 healthy adult males, 48 of whom received ErepoXen while 16 received a
This large Phase I trial was a randomized, double-blind, placebo-controlled single dose study and comprised 64 healthy adult males, 48 of whom received ErepoXen while 16 received a
Under the terms of the collaboration, which uses Vernalis’s proprietary fragment and structure-based drug discovery platform on this undisclosed cancer target, Vernalis will receive fees and a share
Under the terms of the divestment, Evotec has acquired the assets and operations associated with the zebrafish business currently located in Oxfordshire, UK and Singapore for GBP500,000 in
This designation covers Trinam as a treatment for the prevention of de novo stenosis at vascular surgical anastamoses. Trinam is an adenovirus-mediated VEGF D gene delivered with a
Both Misonix and Ekrior will share the “fee for use” revenue for the length of the agreement plus any extension periods. Procedure minimums for “fee per use” revenue
Swiss biopharmaceutical company Basilea Pharmaceutica has reported that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has obtained
US-based healthcare company Myriad Genetics has reported a net profit of $25.31m, or $0.25 per diluted share for the third quarter of fiscal 2009, compared to a net
Novavax, a biotechnology company, has reported vaccination of healthy volunteers in the second clinical trial of its virus-like particle or VLP seasonal influenza vaccine. Building on data from
NiTi Surgical Solutions, a surgical device company, has launched the ColonRing, its new closure technology for colorectal surgery, in the US. The current surgical standard for reconnecting the
Calistoga Pharmaceuticals, a developer of medicines for the treatment of cancer and inflammatory diseases, has closed a $30m series B financing.Investors participating in the financing include Alta Partners,